Sanofi

Haberler

Reuters - 2 gün önce

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds Monte dei Paschi di Siena, Apollo Global Management, updates Coeur Mining Oct 4 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1950 GMT on Friday: ** Italy aims to sell up to around 15% of Monte dei Paschi di Siena BMPS.MI in an upcoming share placement, reducing the government's stake in the bailed-out bank to as low as 12%, two sources close to the matter told Reuters on Friday.

Reuters - 2 gün önce

Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply

UPDATE 2-Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply Adds new sourcing in paragraph 1, adds details throughout Oct 4 (Reuters) - GSK GSK.L , Sanofi SASY.PA and CSL Ltd CSL.AX have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, a health official said on Friday during a press briefing . The move comes as a multi-state outbreak among livestock and poultry has caused human illnesses and infected more than 254 herds in 14 states since March,

Reuters - 2 gün önce

Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply, Bloomberg News reports

Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply, Bloomberg News reports Oct 4 (Reuters) - GSK GSK.L , Sanofi SASY.PA and CSL Ltd CSL.AX have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, Bloomberg News reported on Friday. Reporting by Sriparna Roy in Bengaluru; Editing by Shreya Biswas

Reuters - 2 gün önce

Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show

EXCLUSIVE-Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show Thermo Fisher's Greenville, N.C. plant has been found in breach of US FDA regulations, including twice this year FDA's most recent inspection of Thermo Fisher plant found shortfalls in manufacturing of Sanofi's and AstraZeneca's Beyfortus RSV treatment Sanofi says the FDA findings were addressed and all Beyfortus doses were approved by FDA before they were shipped Adds graphic By Patrick Wingrove Oct 4 (Reu

Reuters - 2 gün önce

Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply- Bloomberg News

MEDIA-Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply- Bloomberg News -- Source link: https://tinyurl.com/4px3r67d -- Note: Reuters has not verified this story and does not vouch for its accuracy

Reuters - 2 gün önce

Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show

CORRECTED-EXCLUSIVE-Thermo Fisher's plant making infant RSV drug breached FDA rules, documents show Corrects paragraph 26 to Novo Holdings from Novo Nordisk Thermo Fisher's Greenville, N.C. plant has been found in breach of US FDA regulations, including twice this year FDA's most recent inspection of Thermo Fisher plant found shortfalls in manufacturing of Sanofi's and AstraZeneca's Beyfortus RSV treatment Sanofi says the FDA findings were addressed and all Beyfortus doses were approved by FDA b

Reuters - 2 gün önce

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Oct 4 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Friday: ** Italian pharma group Recordati RECI.MI said it would buy from Sanofi SASY.PA the global rights to a drug used to treat cold agglutinin disease, a rare autoimmune disorder, for $825 million, sending both stocks up in early trade.

Reuters - 2 gün önce

Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln

UPDATE 1-Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln Adds share moves, trader comment in paragraphs 3-4 Oct 4 (Reuters) - Italian pharma group Recordati RECI.MI said on Friday it would buy from Sanofi SASY.PA the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million, sending both stocks up in early trade.

Reuters - 2 gün önce

Recordati rises after $825 mln global drug rights deal with Sanofi

BUZZ-Recordati rises after $825 mln global drug rights deal with Sanofi ** Shares of Recordati RECI.MI rise around 5% after the Italian pharma group said it would buy from Sanofi SASY.PA the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million ** "Very positive deal which optimises produc

Reuters - 3 gün önce

Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln

Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln Oct 4 (Reuters) - Italian pharma group Recordati RECI.MI said on Friday it would buy from Sanofi SASY.PA the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million. The deal includes additional commercial milestone payments of up to $250 million and will be completed by year-end, subject to regulatory approval, the Italian company said.

Reuters - 3 gün önce

Recordati Signs $825 Mln Deal With Sanofi To Buy Global Rights To Enjaymo

BRIEF-Recordati Signs $825 Mln Deal With Sanofi To Buy Global Rights To Enjaymo Oct 4 (Reuters) - Recordati Industria Chimica e Farmaceutica SpA RECI.MI : SIGNS DEAL WITH SANOFI TO BUY GLOBAL RIGHTS OF ENJAYMO TO PAY UP-FRONT $825 MILLION, ADDITIONAL PAYMENTS CONNECTED TO COMMERCIAL RESULTS UP TO $250 MILLION CLOSING EXPECTED BY YEAR-END, SUBJECT T

Reuters - 3 gün önce

Italy - Factors to watch on October 4

Italy - Factors to watch on October 4 The following factors could affect Italian markets on Friday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy. New items are marked with (*). For a complete list of diary events in Italy please click on IT/DIA . ECONOMY ISTAT releases Q2 deficit/GDP ratio data (0800 GMT) and August retail sales data (1000 GMT).

Reuters - 3 gün önce

Texas attorney general sues insulin makers and pharmacy middlemen over high costs

UPDATE 1-Texas attorney general sues insulin makers and pharmacy middlemen over high costs Adds OptumRx, Cigna and Sanofi responses in paragraphs 11-15 Oct 3 (Reuters) - The Texas attorney general has sued leading insulin manufacturers and pharmacy benefit managers (PBMs), accusing them of collaborating to inflate the cost of insulin. Texas Attorney General Ken Paxton's office said on Thursday it had sued insulin makers Eli Lilly LLY.N , Novo Nordisk NOVOb.CO and Sanofi SASY.PA .

Reuters - 3 gün önce

Texas attorney general sues insulin makers and pharmacy middlemen over high costs

Texas attorney general sues insulin makers and pharmacy middlemen over high costs Oct 3 (Reuters) - The Texas attorney general has sued leading insulin manufacturers and pharmacy benefit managers (PBMs), accusing them of collaborating to inflate the cost of insulin. Texas Attorney General Ken Paxton's office said on Thursday it had sued insulin makers Eli Lilly LLY.N , Novo Nordisk NOVOb.CO and Sanofi SASY.PA .

Reuters - 5 gün önce

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch Oct 2 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. Ageas AGES.BR British holiday group Saga SAGA.L is in talks with Belgium-based insurer Ageas regarding a long-term partnership arrangement for its insurance division, Sky News reported on Tuesday.

Reuters - 5 gün önce

U.S. Applied Materials, Lam Research, S&P Global

U.S. RESEARCH ROUNDUP-Applied Materials, Lam Research, S&P Global Oct 2 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Applied Materials, Lam Research and S&P Global, on Wednesday. HIGHLIGHTS * Applied Materials Inc AMAT.O : Berenberg cuts target price to $246 from $250 * Bank of Hawaii Corp BOH.N : KBW raises to market perform from underperform * First Citizens BancShares FCNCA.O : KBW cuts target price to $2200 fr

Reuters - 5 gün önce

Sanofi Is Said To Ask For Revised Bids For Its Consumer Health Unit In Coming Days - Bloomberg News

BRIEF-Sanofi Is Said To Ask For Revised Bids For Its Consumer Health Unit In Coming Days - Bloomberg News Oct 1 (Reuters) - SANOFI IS SAID TO ASK FOR REVISED BIDS FOR ITS CONSUMER HEALTH UNIT IN COMING DAYS - BLOOMBERG NEWS Source text: https://tinyurl.com/mvjwrj4f Further company coverage: SASY.PA

Reuters - 5 gün önce

WHO recommends maternal vaccine and antibody shot to prevent RSV in infants

UPDATE 1-WHO recommends maternal vaccine and antibody shot to prevent RSV in infants Adds comments from WHO press conference in paragraphs 7 to 10 By Kashish Tandon and Bhanvi Satija Oct 1 (Reuters) - The World Health Organization on Tuesday recommended vaccinating pregnant women and administering infants with an antibody to prevent severe respiratory synctial virus (RSV) infection in newborns.

Reuters - 5 gün önce

WHO recommends maternal shot and antibody therapy to prevent RSV in infants

WHO recommends maternal shot and antibody therapy to prevent RSV in infants Oct 1 (Reuters) - The World Health Organization on Tuesday recommended maternal vaccination and the use of an antibody therapy to prevent respiratory synctial virus (RSV) in infants. The recommendations, to administer both the shot and the antibody or either, come after the WHO's strategic advisory group on immunization met last week.

Reuters - 1 hafta önce

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch Sept 30 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. FRENCH POLITICS France's new Prime Minister Michel Barnier is considering a temporary increase in corporate tax on the country's biggest companies as well as a tax on share buybacks, Le Monde newspaper reported on Sunday.

Şartlar

Popüler varlıklar

Bildirim: XM Group şirketlerinin her biri yalnızca gerçekleştirme hizmeti ve online yatırım platformumuza erişim sağlar. Herhangi bir kişinin web sitesinde bulunan veya web sitesi üzerinden sağlanan içeriği görüntülemesine ve/veya kullanmasına izin vermek, bu hizmeti değiştirmek veya genişletmek amaçlı değildir ve bu hizmeti ne değiştirir ne de genişletir. Bu tür erişim ve kullanım her zaman şunlara tabidir: (i) Şartlar ve Koşullar; (ii) Risk Uyarıları ve (iii) Tam Bildirim. Bu nedenle bu tür içerikler yalnızca genel bilgi amacıyla sağlanır. Özellikle, online yatırım platformumuzun içeriklerinin finans piyasalarında herhangi bir işleme girmek için bir teşvik veya bir teklif olmadığını lütfen dikkate alın. Herhangi bir finans piyasasında yatırım yapmak sermayeniz için önemli düzeyde risk taşır.

Online yatırım platformumuzda yayınlanan tüm materyaller yalnızca eğitim/bilgilendirme amaçlıdır ve finansal tavsiye, yatırım vergisi veya yatırım tavsiyesi ve önerileri ya da yatırım fiyatlarımızın kaydı veya herhangi bir finansal enstrümanda işlem yapılması için bir teklif veya teşvik ya da talep edilmemiş finansal promosyonları içermez ve içerdiği şeklinde bir değerlendirme yapılmamalıdır.

Görüşler, haberler, araştırma, analizler, fiyatlar, diğer bilgiler veya bu web sitesinde bulunan üçüncü taraf sitelere verilen bağlantılar gibi her türlü üçüncü taraf içeriğin yanı sıra XM tarafından hazırlanan içerik de “olduğu gibi” esasına göre, genel piyasa yorumu olarak sağlanır ve bir yatırım tavsiyesi oluşturmaz. Herhangi bir içeriğin yatırım araştırması olarak yorumlanmasıyla ilgili olarak, içeriğin bağımsız yatırım araştırmasını desteklemek üzere tasarlanmış yasal gerekliliklere uygun hazırlanmadığını ve bu amacın güdülmediğini, aynı şekilde ilgili yasalar ve mevzuatlar kapsamında pazarlama iletişimi olarak değerlendirileceğini dikkate almalı ve kabul etmelisiniz. Buradan erişebileceğiniz Bağımsız Olmayan Yatırım Araştırması Bildirimimizi ve yukarıdaki bilgilerle ilgili Risk Uyarımızı okuduğunuzdan ve anladığınızdan emin olun.

Sanofi

Haberler

Şartlar

Popüler varlıklar

XM canlı destek